Aktienanalyse zu Pasithea Therapeutics Corp (KTTA)KTTAPasithea Therapeutics Corp

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pasithea Therapeutics Corp (KTTA) appears to be a good buy right now due to its recent positive news and technical indicators. The stock is currently priced at $0.56, with a 5-day change of +3.82% and a 20-day change of +21.77%. The RSI is at 65.184, indicating strong momentum. Additionally, the company received FDA Orphan Drug Designation for its lead candidate, PAS-004, which could enhance its market position and attract investor interest. However, the main risk is the negative earnings trend, with a net income loss of $10,110,868 in Q4 2025, which investors should monitor closely.